Merck’s Keytruda Further Entrenches Women’s Oncology Position With Cervical Cancer Results

Merck said the KEYNOTE-A18 trial in newly diagnosed, high-risk locally advanced patients met its PFS co-primary endpoint, while results for the OS endpoint were not yet mature.